
1869 articles by Nick Paul Taylor
-
FDA posts guidance on how to simplify updates to antimicrobial resistance tests
Sept. 29, 2023 -
Abbott data suggests GLP-1 drugs a ‘modest accelerator’ for CGMs: analysts
Sept. 29, 2023 -
Artificial heart maker’s cash runway shrinks to 1 month after supply woes hurt sales
Sept. 28, 2023 -
Harbinger Health raises $140M to study blood-based cancer screening test
Sept. 28, 2023 -
Siemens Healthineers buys Aspekt to bolster radiation oncology services
Sept. 27, 2023 -
FDA finalizes guidance on cybersecurity for medical devices
Sept. 27, 2023 -
Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts
Sept. 26, 2023 -
Enovis inks $847M acquisition to boost orthopedic reconstruction business
Sept. 26, 2023 -
Medtronic receives CE mark for CGM sensor, boosting challenge to Abbott and Dexcom
Sept. 25, 2023 -
FDA shares draft medical device harmonization plan to meet MDUFA V goal
Sept. 25, 2023 -
Hologic allies with Bayer to support uptake of contrast-enhanced mammography
Sept. 22, 2023 -
Is bigger better? McKinsey predicts the return of large medtech mergers
Sept. 22, 2023 -
Boston Scientific expects ‘dramatic shift’ to pulsed field ablation to fuel fast growth through 2026
Sept. 22, 2023 -
Limited resources constrain federal oversight of medical device ads, GAO finds
Sept. 21, 2023 -
Stryker adds minimally invasive bunion device to fast-growing extremities portfolio
Sept. 21, 2023 -
CMS leader defends breakthrough device reimbursement proposal at House hearing
Sept. 20, 2023 -
FDA makes device conformity testing scheme permanent to streamline assessments
Sept. 20, 2023 -
J&J starts trial of pulsed field ablation catheter with mapping feedback
Sept. 19, 2023 -
FDA releases draft guidance for studying weight loss devices
Sept. 19, 2023 -
FDA finalizes breakthrough device changes to target health inequities
Sept. 18, 2023 -
Beacon Biosignals receives FDA clearance for sleep tracking headband
Sept. 18, 2023 -
GE HealthCare partners with Mayo Clinic to accelerate work on imaging and AI
Sept. 15, 2023 -
Abbott’s neurostimulator recall, with 73 injuries reported, deemed Class I by FDA
Sept. 14, 2023 -
FDA finalizes biocompatibility guidance for devices that touch the skin
Sept. 14, 2023 -
FDA finalizes combination product guidance 7 years after sharing draft
Sept. 13, 2023